Pelthos Therapeutics Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Q2 2026 net product revenue for Zelsuvmi (molluscum contagiosum treatment) reached $15.4M, up 45% from Q1's $10.7M. Company raised $30M in January 2026 from Horizon Technology Finance under a $50M senior secured term loan facility; additional $10M is available subject to lender discretion based on achieving $42.3M trailing twelve-month revenues. As of June 30, 2026, cash was $24.2M; 11,925 Zelsuvmi units dispensed in Q2 by 4,571 prescribers (48% QoQ increase); >25,000 patients prescribed since July 2025 launch. Two additional products (Xepi, Xeglyze) planned for Q1 2027 and Q3 2027 launches.
Why this rating
Strong revenue growth (45% QoQ) and substantial capital raise ($30M) are meaningful for $6.7M market-cap company. Commercial traction evident. Liquidity secure.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.